en · de · es · fr · pt
semax-notes.peptides6823.com › News › Analytical Testing And Storage — Beginner to Advanced

Analytical Testing And Storage — Beginner to Advanced

By Editorial Desk · published 2026-05-20 · last reviewed 2026-06-03 · News

Everything below concerns RP-HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2026-06-03. Where a claim depends on a specific study, the study is described rather than over-claimed.

Analytical Testing And Storage

Identity and purity of semax are established with reversed-phase high-performance liquid chromatography coupled to ultraviolet detection, usually at 214 nanometres. Mass spectrometry, most often electrospray ionisation in positive mode, confirms the molecular mass and reveals truncated sequences. Amino acid analysis and peptide mapping after enzymatic digestion provide additional structural confirmation. Laboratories typically report purity as the percentage area of the main peak, a figure that does not capture isomeric or oxidised variants unless the method resolves them.

The peptide is prone to several degradation pathways. Oxidation of the methionine residue produces a sulfoxide that elutes close to the parent peak in many chromatographic systems. Hydrolysis of peptide bonds and deamidation of susceptible residues in related sequences also reduce purity over time. Lyophilised material kept dry at minus twenty degrees Celsius and shielded from light is the most stable form commonly described in laboratory practice.

Background and Development

Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.

Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.

Semax at a glance

PropertyValueNotes
AppearanceWhite to off-white powderLyophilised solid
Solubility classFreely soluble in waterAlso dissolves in aqueous buffers
Typical storage temperature-20 °CDry, desiccated, protected from light
Typical analytical methodRP-HPLC with UV detectionOften paired with LC-MS
Water contentReported as Karl Fischer valueFreeze-dried material is hygroscopic

Mechanism and Research Context

Published studies examine a fairly narrow set of endpoints. Rodent experiments commonly measure maze learning, infarct volume after induced ischemia, and tissue levels of neurotrophic factors. Clinical reports from Russian centres describe attention, memory and recovery scores in patients after stroke or transient ischemic attack. Most of those human studies are small and few have been repeated by independent groups. Outcome measures differ between studies, which limits direct comparison.

Circulation time for the peptide is short because peptidases cleave it readily. The Pro-Gly-Pro tail is thought to slow breakdown compared with the bare ACTH fragment, but the gain appears modest. Absorption after intranasal dosing is limited, and only a fraction of a dose is expected to reach the central nervous system. Laboratory concentrations therefore sit well above levels achieved systemically, a gap that complicates translation from bench findings to clinical claims.

Related pages on this site

研发背景与监管地位

各国监管态度分化明显。俄罗斯按处方药管理,部分东欧国家留有使用记录;欧盟与美国未批准其作为药物上市,市面流通品通常标注为研究用化学品。身份差异意味着标示含量、纯度与无菌性缺少统一核查。体育领域还牵涉反兴奋剂名录,跨境携带则受目的地药品法规约束。

Semax 是人工设计的七肽,序列为 Met-Glu-His-Phe-Pro-Gly-Pro,骨架取自促肾上腺皮质激素片段 ACTH(4-10)。它于二十世纪八十年代在苏联的分子遗传学研究机构内合成。设计目标是保留该片段与注意力和记忆相关的活性,同时剔除促皮质激素释放等内分泌作用。此后俄罗斯将其登记为药品并进入临床使用。

当时的短肽研究普遍关注能否穿越血脑屏障、在低剂量下产生中枢效应,Semax 属于这一路线。鼻内给药是其主要使用方式,俄语文献报道的适应症涵盖缺血性卒中、短暂性脑缺血发作、认知功能减退以及视神经病变。这些研究大多发表在当地期刊上,样本规模与终点设置同西方试验惯例存在差异,国际同行对其临床证据的强度看法不一。

Supporting material

== Endolithic parasitism == Until the 1990s phototrophic endoliths were thought of as somewhat benign, but evidence has since surfaced that phototrophic endoliths (primarily cyanobacteria) have infested 50 to 80% of midshore populations of the mussel species Perna perna located in South Africa. The infestation of phototrophic endoliths resulted in lethal and sub-lethal effects such as the decrease in strength of the mussel shells. Although the rate of thickening of the shells were faster in more infested areas it is not rapid enough to combat the degradation of the mussel shells.

Irène Joliot-Curie (Physics, 1935) Julian Schwinger (Physics, 1965) Pyotr Kapitsa (Physics, 1978) Frank Wilczek (Physics, 2004) Michael Kremer (Economics, 2009) Jack Szostak (Physiology or Medicine, 2009) Robert Lefkowitz (Chemistry, 2012) Victor Ambros (Physiology or Medicine, 2024, obtained Polish citizenship in 2026) John Hopfield (Physics, 2024)

== History == The orexin neuropeptides were discovered in 1998 and the role of the orexin system in the etiology of narcolepsy was identified between 1999 and 2000. Subsequent research further established the role of the orexin system in sleep–wake regulation. Due to the promising potential of orexin system modulation in the treatment of sleep disorders, these findings led to translational efforts to bring orexin receptor modulators to medicine as therapeutic agents. Suvorexant was developed by Merck. It entered clinical development in 2006 and was first described in the medical literature in 2010. The medication was approved by the FDA for the treatment of insomnia in the United States on 13 August 2014. Suvorexant was initially released November 2014 in Japan, then later reached the United States in February 2015, Australia in November 2016, and Canada in November 2018. It was the first orexin receptor antagonist to be introduced for medical use, and was followed by lemborexant in 2019 and daridorexant in 2022. Development of almorexant (ACT-078573) and filorexant (MK-6096) was discontinued, while seltorexant (MIN-202, JNJ-42847922) and vornorexant (ORN-0829, TS-142) are still in clinical trials. Suvorexant marketing exclusivity in the United States was set to expire in January 2023 and patent protection is set to expire in 2029 to 2033.

Sources: en.wikipedia.org

Notes from published material

Very high product yields are usually accomplished without the formation of by-products or the synthesis of cell mass. For example, with a synthetic enzyme pathway, from the reaction with starch and water C6H10O5 (l) + 7 H2O (l) → 12 H2 (g) + 6 CO2 (g), nearly 12 H2 has been produced per glucose unit of polysaccharides and water, three times of the theoretical yield of the best anaerobic hydrogen-producing microorganisms. In vitro biosystems can implement some biological reactions that living microbes or chemical catalysts cannot implement before. For example, beta-1,4-glucosidic bond linked cellulose can be converted to alpha-1,4-glucosidic bond linked starch by a mixture of intracellular and extracellular enzymes in a single reaction container. Enzymatic systems, without the barrier of cellular membrane, usually have faster reaction rates than microbial systems. For instance, enzymatic fuel cells usually have much higher power outputs than microbial fuel cells. Enzyme cocktails can tolerate toxic compounds better than microorganisms. Enzyme mixtures usually work under broad reaction conditions, such as high temperature, low pH, the presence of organic solvents or ionic liquids.

=== Special populations === Pregnancy: studies in lab animals showed no harm to the baby. However, a comparable well-controlled study has not been performed in pregnant women. Nursing: breast milk has been shown to contain small amounts of labetalol (0.004% original dose). Prescribers should be cautious in the use of labetalol for nursing mothers. Pediatric: no studies have established safety or usefulness in this population. Geriatric: Due to an increased likelihood of experiencing orthostatic symptoms such as dizziness, product labelling recommends that elderly patients receive counselling regarding these side effects during labetalol treatment. Furthermore, because drug elimination is reduced in older demographics, lower maintenance doses are typically sufficient to achieve therapeutic effects.

The Blood resource focus on the individual protein levels in blood of both healthy individuals and patients diagnosed with various diseases. Here you can explore: - The individual protein levels in blood from healthy individuals and patients diagnosed with diseases. - The longitudinal blood protein levels in healthy individuals during two years. - The longitudinal blood protein levels in children through puberty. - The effect of age, BMI and sex on the individual protein levels in blood. - The levels of plasma proteins using immune assays and mass spectrometry. The Subcellular resource of the Human Protein Atlas provides high-resolution insights into the expression and spatiotemporal distribution of proteins encoded by 13603 genes (67% of the human protein-coding genes) as well as predictions for an additional 3459 secreted- or membrane proteins, covering a total of 17062 genes (85% of the human protein-coding genes). For each gene, the subcellular distribution of the protein has been investigated by immunofluorescence (ICC-IF) and confocal microscopy in up to three different cell lines, selected from a panel of 42 cell lines used in the subcellular resource. Upon image analysis, the subcellular localization of the protein has been classified into one or more of 35 different organelles and fine subcellular structures. For some genes, the protein has also been stained in up to three ciliated cell lines, induced pluripotent stem cells (iPSCs) and/or in human sperm cells.

In animals, the main excretory products are carbon dioxide, ammonia (in ammoniotelics), urea (in ureotelics), uric acid (in uricotelics), guanine (in Arachnida), and creatine. The liver and kidneys clear many substances from the blood (for example, in renal excretion), and the cleared substances are then excreted from the body in the urine and feces. Aquatic animals usually excrete ammonia directly into the external environment, as this compound has high solubility and there is ample water available for dilution. In terrestrial animals, ammonia-like compounds are converted into other nitrogenous materials, i.e. urea, that are less harmful as there is less water in the environment and ammonia itself is toxic. This process is called detoxification.

Sources: en.wikipedia.org

Further detail

== Structure == The Walker motifs are a telltale protein sequence motif for nucleotide binding and hydrolysis. Beyond this broad function, the Walker motifs can be found in almost all natural ATPases, with the notable exception of tyrosine kinases. The Walker motifs commonly form a Beta sheet-turn-Alpha helix that is self-organized as a Nest (protein structural motif). This is thought to be because modern ATPases evolved from small NTP-binding peptides that had to be self-organized. Protein design has been able to replicate the ATPase function (weakly) without using natural ATPase sequences or structures. Importantly, while all natural ATPases have some beta-sheet structure, the designed "Alternative ATPase" lacks beta sheet structure, demonstrating that this life-essential function is possible with sequences and structures not found in nature.

== Further reading == Rhodesians Never Die, Godwin, P. & Hancock, I., 1995. Baobab Books, Harare, Zimbabwe. Pollard, William C. A Career of Defiance: The Life of Ian Smith, Agusan River Publishing Co., 1992. Topeka, KS. McLaughlin, John . "Ian Smith and the Future of Zimbabwe," The National Review, October 30, 1981, pp. 2168–70. Facts on File, 1984 ed., p. 574.

Solutions for total parenteral nutrition may be customized to individual patient requirements, or standardized solutions may be used. The use of standardized parenteral nutrition solutions is cost-effective and may provide better control of serum electrolytes. Ideally each patient is assessed individually before commencing on parenteral nutrition, and a team consisting of specialised doctors, nurses, clinical pharmacists, and registered dietitians evaluate the patient's individual data and decide what PN formula to use and at what infusion rate. For neonates, specialist formulations are required . For energy only, intravenous sugar solutions with glucose (dextrose) are generally used. This is not considered to be parenteral nutrition as it does not prevent malnutrition when used on its own. Standardized solutions may also differ between developers. Following are some examples of what compositions they may have. The solution for normal patients may be given both centrally and peripherally.

=== Influence on other special forces === Following the post-war reconstitution of the Special Air Service, other countries in the Commonwealth recognised their need for similar units. The Canadian Special Air Service Company was formed in 1947, being disbanded in 1949. The New Zealand Special Air Service squadron was formed in June 1955 to serve with the British SAS in Malaya, which became a full regiment in 2011. Australia formed the 1st SAS Company in July 1957, which became a full regiment of the Special Air Service Regiment (SASR) in 1964. On its return from Malaya, the C (Rhodesian) Squadron formed the basis for creation of the Rhodesian Special Air Service in 1961. It retained the name "C Squadron (Rhodesian) Special Air Service" within the Rhodesian Security Forces until 1978, when it became 1 (Rhodesian) Special Air Service Regiment. Non-Commonwealth countries have also formed units based on the SAS. The Belgian Army's Special Forces Group, which wears the same capbadge as the British SAS, traces its ancestry partly from the 5th Special Air Service of the Second World War. The French 1st Marine Infantry Parachute Regiment (1er RPIMa) can trace its origins to the Second World War 3rd and 4th SAS, adopting its "who dares wins" motto. The American unit, 1st Special Forces Operational Detachment-Delta, was formed by Colonel Charles Alvin Beckwith, who served with 22 SAS as an exchange officer, and recognised the need for a similar type of unit in the United States Army.

Other notable mutations identified in ICP patients include ones in the farnesoid X receptor (FXR), a nuclear receptor in hepatocytes which activates transcription of MDR3 and BSEP upon binding intracellular bile acids, thereby increasing canalicular bile efflux.

Sources: en.wikipedia.org

Frequently asked questions

How is semax purity measured?

Reversed-phase high-performance liquid chromatography is the standard method, with detection in the ultraviolet range. Peak area percentage yields a purity figure for the main component. Mass spectrometry is normally run alongside to confirm molecular identity.

How should semax powder be stored?

Dry lyophilised powder is generally kept at minus twenty degrees Celsius, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they encourage aggregation and moisture uptake. Solutions are less stable than the solid form and degrade faster at room temperature.

Does a certificate of analysis guarantee quality?

A certificate documents what the supplier measured, not what an independent party confirmed. Methods, instruments and acceptance criteria can differ between suppliers. Third-party testing is the usual way to resolve discrepancies.

Where was Semax developed?

It originated at the Institute of Molecular Genetics in Moscow during the 1980s. The work was carried out by a Russian research group that specialized in peptide neuropharmacology.

Network